am 3. Januar 2000
Working in a small start up biotech company, I found many parallels with the "Vertex Story" and the company I work for. I was able to identify with the pressure of finding a lead drug candidate (though not quite as intense as those Vertex scientists who went to Hell and back), the rallying of all the employees to do the best thing for the company, and hoping that upper management can keep raising the cash to keep us going. I might add that raising money now has become even more challenging with the advent of the Internet and the dot com companies that have taken a huge chunk of the available investment dollars. The story that unfolds in this book is a very good depiction of how difficult it is to find a drug candidate let alone one that will make it all the way through the FDA-required clinical trials. The clinical trials, although outside the scope for this book, are a significant part of getting a drug to the market and present their own set of challenges. A good book to get a pretty good feel of this is HER-2 by Robert Bazell about the road Genentech's Herceptin took before finally receiving FDA approval to treat breast cancer.
am 24. März 1998
I first read this book nearly two years ago as research for a novel I was writing. Recently, I turned to it once more to pick up a few terms and found myself reading chapter after chapter!
This non-fiction tale has enough twists and turns and drama to match any thriller on the market. An informative and engaging tale of a pharmaceutical start-up and the people involved. Joshua is interesting enough that the book could have been solely about him, but he isn't the only one. All of the players in this ego-driven mega-drama are interesting on many levels.
Who would I reccomend this book to? Anyone who likes a well-told story. A background in medicine is not needed, and neither is a knowledge of business practices. All you need to enjoy this book is a brain . . . and a night light because you'll be reading this book deep into the night.
am 12. Januar 1998
Barry's Werth spent several years with the scientists and bio-venturers who formed Vertex Pharmaceuticals. The work paid off in an insightful and entertaining book. The Billion Dollar molecule is the holy grail of the researchers in today's pharmaceutical world, and this book shows how they go about attaining it. A remarkably easy book to read even if you don't know a protein from a Springsteen. The reader can find something valuable from all angles. Read it as a science book, a thriller, a business narrative, or a straight novel, you'll find delight here.
am 3. Mai 1998
Barry Werth has managed in this book to capture the essence of the excitement, frustrations, suffering and satisfaction of being in a successful high-tech startup company. Having had unprecedented access to staff at Vertex and its collaborators, he has managed to reconstruct events from all angles. Werth presents his story in a compelling dramatic style, from the heady heights of scientific discovery, to the depths of VC capriciousness.
This book is highly suggested reading in our new startup!
am 6. Januar 1999
A well-told, vivid story about real life drug development, executed with a sharp observer's eye and an even hand. Hardly a gushing account of medical miracles in the making, but by no means industry bashing either. Rather, an inside look at real people in a fascinating world. This book never quite got the critical acclaim that it deserved.